Participant flow

Adjuvant Bortezomib Maintenance Therapy After Autologous Peripheral Stem Cell Transplantation in Treating Patients With Intermediate or Advanced Multiple Myeloma · Source last updated 2020-08-17

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups

1. description

   bortezomib administration beginning 3-4 month after the day of transplantation after resolution of bone marrow transplant toxicities

   id

   FG000

   title

   Bortezomib

periods

1. drop Withdraws

   1. reasons

      1. group Id

         FG000

         num Subjects

         8

      type

      Relapsed

   2. reasons

      1. group Id

         FG000

         num Subjects

         3

      type

      Death

   3. reasons

      1. group Id

         FG000

         num Subjects

         2

      type

      Withdrawal by Subject

   milestones

   1. achievements

      1. group Id

         FG000

         num Subjects

         30

      type

      STARTED

   2. achievements

      1. group Id

         FG000

         num Subjects

         17

      type

      COMPLETED

   3. achievements

      1. group Id

         FG000

         num Subjects

         13

      type

      NOT COMPLETED

   title

   Overall Study

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice